Cross-Talk between the TGF-β and Cell Adhesion Signaling Pathways in Cancer

IF 3.2 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

International Journal of Medical Sciences Pub Date : 2024-05-13 DOI:10.7150/ijms.96274

Jiahao Liao, Rentang Chen, Bihua Lin, Runhua Deng, Yanfang Liang, Jincheng Zeng, Sha Ma, Xianxiu Qiu

{"title":"Cross-Talk between the TGF-β and Cell Adhesion Signaling Pathways in Cancer","authors":"Jiahao Liao, Rentang Chen, Bihua Lin, Runhua Deng, Yanfang Liang, Jincheng Zeng, Sha Ma, Xianxiu Qiu","doi":"10.7150/ijms.96274","DOIUrl":null,"url":null,"abstract":"Transforming growth factor-β (TGF-β) is strongly associated with the cell adhesion signaling pathway in cell differentiation, migration, etc. Mechanistically, TGF-β is secreted in an inactive form and localizes to the extracellular matrix (ECM) via the latent TGF-β binding protein (LTBP). However, it is the release of mature TGF-β that is essential for the activation of the TGF-β signaling pathway. This progress requires specific integrins (one of the main groups of cell adhesion molecules (CAMs)) to recognize and activate the dormant TGF-β. In addition, TGF-β regulates cell adhesion ability through modulating CAMs expression. The aberrant activation of the TGF-β signaling pathway, caused by abnormal expression of key regulatory molecules (such as Smad proteins, certain transcription factors, and non-coding RNAs), promotes tumor invasive and metastasis ability via epithelial-mesenchymal transition (EMT) during the late stages of tumorigenesis. In this paper, we summarize the crosstalk between TGF-β and cell adhesion signaling pathway in cancer and its underlying molecular mechanisms.","PeriodicalId":14031,"journal":{"name":"International Journal of Medical Sciences","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/ijms.96274","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Transforming growth factor-β (TGF-β) is strongly associated with the cell adhesion signaling pathway in cell differentiation, migration, etc. Mechanistically, TGF-β is secreted in an inactive form and localizes to the extracellular matrix (ECM) via the latent TGF-β binding protein (LTBP). However, it is the release of mature TGF-β that is essential for the activation of the TGF-β signaling pathway. This progress requires specific integrins (one of the main groups of cell adhesion molecules (CAMs)) to recognize and activate the dormant TGF-β. In addition, TGF-β regulates cell adhesion ability through modulating CAMs expression. The aberrant activation of the TGF-β signaling pathway, caused by abnormal expression of key regulatory molecules (such as Smad proteins, certain transcription factors, and non-coding RNAs), promotes tumor invasive and metastasis ability via epithelial-mesenchymal transition (EMT) during the late stages of tumorigenesis. In this paper, we summarize the crosstalk between TGF-β and cell adhesion signaling pathway in cancer and its underlying molecular mechanisms.

查看原文本刊更多论文

癌症中 TGF-β 和细胞粘附信号通路之间的交叉对话

转化生长因子-β（TGF-β）与细胞分化、迁移等过程中的细胞粘附信号通路密切相关。从机理上讲，TGF-β 以非活性形式分泌，并通过潜伏的 TGF-β 结合蛋白（LTBP）定位于细胞外基质（ECM）。然而，成熟 TGF-β 的释放对于激活 TGF-β 信号通路至关重要。这一过程需要特定的整合素（主要的细胞粘附分子（CAM）之一）来识别和激活休眠的 TGF-β。此外，TGF-β 通过调节 CAMs 的表达来调节细胞粘附能力。关键调控分子（如 Smad 蛋白、某些转录因子和非编码 RNA）的异常表达导致 TGF-β 信号通路的异常激活，从而在肿瘤发生的晚期通过上皮-间质转化（EMT）促进肿瘤的侵袭和转移能力。本文总结了肿瘤中 TGF-β 与细胞粘附信号通路之间的相互影响及其潜在的分子机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Medical Sciences MEDICINE, GENERAL & INTERNAL-

CiteScore

7.20

自引率

0.00%

发文量

185

审稿时长

2.7 months

期刊介绍： Original research papers, reviews, and short research communications in any medical related area can be submitted to the Journal on the understanding that the work has not been published previously in whole or part and is not under consideration for publication elsewhere. Manuscripts in basic science and clinical medicine are both considered. There is no restriction on the length of research papers and reviews, although authors are encouraged to be concise. Short research communication is limited to be under 2500 words.